ASH 2020: Anti-CD117 monoclonal antibody JSP191 for the treatment of severe combined immunodeficiency disease (SCID)

Severe combined immunodeficiency disease (SCID) is a group of heterogeneous diseases caused by the development and dysfunction of T- and B-cells (cell immune and body fluid immunity).
hematopoietic cell transplantation is the only treatment for SCID, in which standard chemotherapy is performed before the transplant to reduce the number of blood stem cells in the bone marrow, thus making room for donor blood stem cell implants.
JSP191 is designed to replace chemicals that can damage DNA.
biotechnology company Jasper Therapeutics today released the latest data from the ongoing JSP191 Multi-Center Phase I clinical trial, an anti-CD117 monoclonal antibody for the treatment of severe combined immunodeficiency disease (SCID).
data from an unployed SCID patient (a 6-month-old baby) in a Phase I trial show that single dose of JSP191 before stem cell transplantation can effectively establish continuous supply chimosa.
data were published by Dr Rajni Agrawal-Hashmi of Stanford University at the 62nd Annual Meeting of the American Society of Hematology (ASH).
. Kevin N. Heller, Executive Vice President of Research and Development at Jasper Therapeutics, said, "We have previously demonstrated that JSP191 can be successfully used as a single conditioner for patients with previously failed transplants.
data, presented at ASH 2020, show the success of SCID babies undergoing their first transplant, demonstrating the feasibility of using JSP191 as an alternative to chemotherapy that currently consumes stem cells before transplantation."
。